MedTrace Logo

Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer

NCT01518621 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-03-13

No results posted yet for this study

Summary

To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT alone, without significantly increasing the risk of side effects or lowering quality of life.

Conditions

Interventions

RADIATION

Radiation

Whole brain radiation

DRUG

Radiation plus erlotinib

Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Odd Terje Brustugun, MD PhD · Norwegian Radium Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2017-12-10
Completion
2018-12-10

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01518621 on ClinicalTrials.gov